XRX
48
2
UNH
42
6
CAT
47
3
EMN
40
5
UA
48
6
VRSN
59
4
BF.B
35
2
GIS
47
13
PHM
44
4
CTSH
55
3
MSFT
55
2
STT
48
4
ADBE
50
3
NEE
39
9
ABT
54
4
CMCSA
49
3
LOW
42
14
LUV
45
3
CVX
25
14
NI
63
5
XRX
48
2
UNH
42
6
CAT
47
3
EMN
40
5
UA
48
6
VRSN
59
4
BF.B
35
2
GIS
47
13
PHM
44
4
CTSH
55
3
MSFT
55
2
STT
48
4
ADBE
50
3
NEE
39
9
ABT
54
4
CMCSA
49
3
LOW
42
14
LUV
45
3
CVX
25
14
NI
63
5
Financhill
Back

Relmada Therapeutics 10K Form

Sell
27

RLMD
Relmada Therapeutics

Last Price:
$0.36
Seasonality Move:
8.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLMD News And Ratings

See the #1 stock for the next 7 days that we like better than RLMD

RLMD Financial Statistics

Sales & Book Value

Annual Sales: $5.1K
Cash Flow: $-16.7M
Price / Cash Flow: 0
Annual Sales: $1.58
Price / Book: 0.23

Profitability

EPS (TTM): -2.86000
Net Income (TTM): $-86.5M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Relmada Therapeutics Earnings Forecast

Key Relmada Therapeutics Financial Ratios

  • The Selling, General & Administrative Expenses for RLMD have been equal to 898.83% of Gross Profit Margin.
  • The Interest Expense is -9.27% of Operating Income.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Relmada Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RLMD
CUSIP: 75955J
Website: relmada.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLMD Technical Analysis vs Fundamental Analysis

Sell
27
Relmada Therapeutics (RLMD) is a Sell

Is Relmada Therapeutics a Buy or a Sell?